…a new method for limiting the development of fatty liver. For the study, the researchers had access to a drug candidate in the form of an antibody to the protein…
…The bispecific antibody company is currently working with Summit Therapeutics on the development of ivonescimab. The candidate, originally discovered by Akeso, combines the power of immunotherapy through a blockade of…
…cash, and the lead asset acquired is a monoclonal antibody for inflammatory bowel disease. July 2024: Sionna Therapeutics, based in the United States, has partnered with AbbVie, also a U.S….
…Her’s own company, AP Biosciences, is also advancing multiple bispecific antibody candidates through the clinic. The company’s lead candidate is AP505, which also targets PD-L1 and VEGF. “By blocking PD-L1,…
…Alchemab Therapeutics (in collaboration with Eli Lilly) Technology: B-cells sequencing Candidates: Multiple antibodies Recent news: Collaboration with Eli Lilly to develop ALS candidates Alchemab Therapeutics is a U.K.-based biopharmaceutical company…
…monoclonal antibody candidate. This is being developed in collaboration with OncoC4, Inc., and is currently in a pivotal phase 3 trial for patients with non-small cell lung cancer (NSCLC) who…
…therapy that is designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of monoclonal antibodies. This way, the drug can kill auto-antibody producing B cells. The candidate is also being…
…display library engineered to include more than 200 billion unique sequences and capable of identifying high-affinity antibody candidates using Bio-Rad’s newly developed SpyDisplay selection technology. The Pioneer antibody library is…
…pan‑immunoglobulin (Ig) G protease sculpting (Sc) enzyme candidate (S-1117) and a PD-1 agonist:Fc gamma receptor IIb selective Dual-cell Bidirectional (DcB) antibody candidate (S-4321). The fundraising will also allow Seismic to…
…designation from the EMA, the company looks to submit its candidate for regulatory approval next year. Moreover, Bavarian Nordic has other vaccine candidates in the mix. MVA-BN WEV is being…
…is a monoclonal antibody that works by binding to TIGIT, which could activate the immune system to attack cancer cells. Typically, a fragment crystallizable (Fc) region in a monoclonal antibody,…
…jointly work to research, develop, and commercialize novel monospecific antibody candidates for various cancer indications. Since 2015, the companies have been working on the joint development of bispecific cancer antibodies…